In Brief: Medstone International
This article was originally published in The Gray Sheet
Medstone International: Agrees to an out-of-court settlement of the shareholders' lawsuit initiated against it and certain officers and directors in October 1989. The settlement agreement calls for the lithotripsy firm to pay $5.5 mil. in cash of a total $6 mil. settlement. The settlement "is not an admission of any liability," Medstone says. The suit alleged that the firm withheld adverse material information at the time of its initial public offering in June 1988...
You may also be interested in...
Perrigo, Pfizer want the US FDA to postpone its March 1 deadline for conducting nitrosamine risk assessments. Generics exec cites“serious compliance challenges” in conducting these assessments due to difficulty in finding the right lab equipment necessary to quantify nitrosamine daily intake limits.
Deal snapshot: For $425m up front, the pharma obtains a Phase III recombination fusion protein that shows ability to improve hospitalized patients’ clinical status and reduce risk of death.
Previous businesses FDA warned about COVID-19 claims for chlorine dioxide, a bleach solution, were marketing dietary supplements unlawfully. But Pro Breath MD's oral rinses available under the Dentist Select and OraCare brands are allowed and FDA isn’t asking the firm to discontinue distribution.